Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 546 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 546 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $45.59, for a total value of $24,892.14. Following the completion of the sale, the chief executive officer now directly owns 672,518 shares of the company’s stock, valued at $30,660,095.62. The trade was a 0.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $45.62 on Wednesday. The business’s fifty day moving average is $46.22 and its 200-day moving average is $46.48. The stock has a market cap of $2.71 billion, a PE ratio of -12.67 and a beta of 1.85. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90.

Analyst Ratings Changes

Several analysts have commented on TWST shares. Leerink Partners upped their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. TD Cowen reiterated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. lifted its holdings in shares of Twist Bioscience by 67.5% during the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after buying an additional 82,953 shares during the last quarter. Oddo BHF Asset Management Sas bought a new stake in shares of Twist Bioscience in the third quarter valued at approximately $3,302,000. Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience in the third quarter valued at approximately $95,000. Franklin Resources Inc. raised its stake in shares of Twist Bioscience by 3.4% in the third quarter. Franklin Resources Inc. now owns 252,064 shares of the company’s stock valued at $11,756,000 after purchasing an additional 8,308 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience in the third quarter valued at $34,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.